Speedy new cell therapy shows promise for tough lymphoma
NCT ID NCT05400109
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new, fast-made CAR-T cell therapy (UF-KURE19) for people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose in 21 adults. Researchers also look at how well the therapy shrinks tumors and how reliably the cells can be made quickly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
-
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- A smarter steroid schedule might tame Chemotherapy's blood sugar spike
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out